European Commission Consults On New Clinical Trial Inspection And GMP Rules
This article was originally published in SRA
Executive Summary
The European Commission is in the early stages of drafting legislation that will describe in detail how inspections of clinical trials are to be conducted in the EU and elsewhere once the provisions of the new clinical trials legislation kick in around mid-2016. It is also drafting new guidance on the manufacture of investigational medicinal products (IMPs) used in clinical trials.
You may also be interested in...
EU Finalizes GMP Rules, Inspection Procedures For Investigational And Finished Drugs
Two new legal acts have been adopted by the European Commission specifying updated good manufacturing practice requirements for investigational medicinal products and finished medicines. The legislation take into account recent updates to the EU rules on the safety of medicines.
EU Close To Finalizing Revised GMP And Inspection Rules For Clinical Trials
The European Commission has issued revised delegated legislation explaining new GMP requirements and inspection arrangements for investigational medicinal products that will come into play when the EU Clinical Trials Regulation kicks in.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.